Tomer Stavitsky’s Post

A First Step into bringing Novel US FDA Breakthrough technology to the US , A Giant Leap of Hope & Promise for US based Patients suffering from complex Coronary occlusive vascular disease . Concept Medical is proud to announce commencement of its Pivotal US FDA Investigational Devise Exemption Study for the treatment of Instent Restenosis with Magic Touch SCB - The World's 1st CE commercialized Novel Sirolimus Drug Coated Balloon , offering a safer and effective alternative for treatment of complex coronary disease such as InStent Restenosis . We are thankful to Dr Ajay Kirtane , Dr Azeem Latib , the principal investigators of the study and all the US study investigators supporting the enrollment and treatment in this pivotal multi- centered Randomised clinical trial. With Over 23K patients touched with Its clinical trial program with results that are altering standards of care and shaping the future of percutaneous treatment of occlusive vascular disease with over 180 K patients treated in real world setting with its solutions accross vascular disease , this milestone is indeed an important step to extend these proven technlogies to ailing patients in the US # Worlds 1st CE commercialized Sirolimus DCB #US FDA Breakthrough Devices # Largest and Longest Studied Clinical trial program touching over 23 K patients # over 180 K patients treated - Confidence Inspired by Real World Use.

VESTECK Wins!! VESTECK, Inc. and the "SUTURE-TIGHT"tm catheter were selected the top innovative technology in the LIFE SCIENCES TRACK at the inaugural Venture Forum. "SUTURE-TIGHT"tm is a platform catheter, preloaded with NITINOL sutures. Physicians around the world tell us they will use these sutures in the aortic repair space, structural heart, peripheral vascular/venous and general surgical markets. Clinicians have asked VESTECK and "SUTURE-TIGHT"tm to initially target the aortic repair space. The peer reviewed literature documents that EVAR/TEVAR patients will benefit from increased durability and aneurysm sac shrinkage. Kyto Technology and Life Science Inc successfully launched their first innovator/investor conference via virtual presentations and a virtual partnering platform.

📆 Join us and Dr. Claudio Iovino (MD, PhD) in our In-sight Webinar Series—a recurring appointment with the latest insight on posterior segment care. Dr. Iovino shares two major case reports from LightWave I, our multi-centric clinical trial focused on the application of LM® LLLT (PBM) technology in the management of AREDS 2 & 3 dry Age-related Macular Degeneration (dAMD) with eye-light®. The case reports, recently accepted for publication at ARVO 2024, present two impressive cases of patients with dry AMD and non-neovascular AMD who benefitted from LM® LLLT therapy. In the keynote Dr. Iovino will discuss: ◽ How dAMD will increasingly impact modern society ◽ How LM® LLLT photobiomodulation technology works, and the promise it holds ◽ LightWave I Clinical Trial: what it is, what we're doing, where we're going ◽ Case Report 1: AREDS 3 dry AMD ◽ Case Report 2: Non-neovascular AMD w/ PED and Subretinal Fluid ◽ LightWave II Clinical Trials: how to apply The event will be followed by a Live Q&A session with our Medical Affairs Team. Register now for groundbreaking AMD insights with Dr. Claudio Iovino! Secure your spot here 👇 https://lnkd.in/dXYr9r5Z #espansionegroup #scienceonward #lightmodulation #PBM #dAMD

A day of firsts in UK, congratulations to Professor Alex Green from the John Radcliffe Hospital and Dr Barani G from Leeds Teaching Hospital and their entire SCS teams for completing the first Eterna™ SCS system implants today. We're proud to partner with you in offering this technology to patients. The Eterna™ SCS System is up to 58% smaller than other rechargeable SCS systems,1* which could be a more comfortable option for chronic pain patients.2 This latest spinal cord stimulation (SCS) innovation from @Abbott|Neuromodulation is now available in the UK. Learn more at Eterna.Abbott/EMEA    #AbbottProud Hayley Dunn, Edward Blowers, Gemma Mercer, Jenny Pritchard, Sarah Cooper   Important Safety Info: https://bit.ly/isi_int   *Smallest size determined by volume in cubic centimeters. Based off comparison to volumetric measurement of the following IPGs: Boston Scientific‡ WaveWriter Alpha‡ 16: 20.1 cc; Medtronic‡ Intellis‡: 13.9 cc; Nevro‡ Omnia‡: 26 cc; Saluda‡ Evoke‡: 33 cc. 1. Abbott. OUS Eterna™ SCS IPG Size Comparison Memo (MAT-2312887). 2024. 2. Baranidharan G, Bretherton B, Richert G, et al. Pocket pain, does location matter: a single-centre retrospective study of patients implanted with a spinal cord stimulator. Reg Anesth Pain Med. 2020;45(11):891-897. doi:10.1136/rapm-2020-101752

⚡️We are pleased to share a new publication: Hemodynamical Evaluation of a New Surgically Implanted Pulsatile Right Ventricular Assist Device Driven by a Conventional Intra-Aortic Balloon Pump Console by Dr. Sara Knigge, Dr. Günes Dogan et all. ASAIO Journal 2024. 🔸 New Pulsatile Ventricular Assist Platform, pVAP 🔸 This platform builds on the proven IVAC 2L technology 🔸 Driven by standard IABP console 🔸 Compatible with all available standard cannulas  The main findings indicate that the pVAP is feasible and effective. ✅ the output flow of the pVAP is directly influenced by the pressure in the output chamber; ✅ the pVAP produces an output of 2.7 L/min; ✅ the pVAP has a minor, but observable, hemodynamic effect in healthy individuals; ✅ in cases of acute RVF, activating the pVAP significantly improves hemodynamics in both the pulmonary and aortic circulations.   🚩Conclusion: This initial experience with the pVAP prototype demonstrates its feasibility as a VAD and effectiveness in restoring hemodynamics in porcine models of acute RVF. 👉 Full publication: https://lnkd.in/ecgtY4Qk   Special thanks to Prof. Dr. J. D. Schmitto, MD, PhD, MBA, FRCS(Glasg) FACS, Director of the Mechanical Circulatory Support Medizinische Hochschule Hannover and team. Oren Malchin   Would you like to know more? Please leave a message via our website: https://lnkd.in/eRSFAWJV   #PulseCath #iVAC2L #MCS #pVAD #interventionalcardiology #medicaldevices #healthcareinnovation #protectedPCI

If you missed the CIRSE webinar, held in collaboration with Inari Medical, on treating acute PE with bloodless thrombectomy or want to rewatch it, it is now available in the CIRSE Library! ➡️ https://t.ly/CdM9b #CIRSEwebinar #CIRSElibrary #interventionalradiology 

👨⚕️ Axonics, Inc. Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15™) and is paired with the same tined lead and intuitive, easy to use patient remote control. The R20 also provides physicians and their patients with enhanced programming capabilities and expanded MRI labeling. “Delivering a superior patient experience has been at the forefront of our SNM development efforts,” said Raymond W. Cohen, chief executive officer. “Patients with overactive bladder tell us that first and foremost, they value efficacy and a long-lived solution to address their chronic condition. The R20 represents another significant breakthrough for rechargeable neuromodulation devices and underscores Axonics’ commitment to continuous innovation. We are confident that our keen focus on the incontinence patient population has the potential to drive significant market expansion in both the U.S. and international markets in the years ahead.” Read more online: https://lnkd.in/esPq-P-W 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #axonics #neuromodulation

🚨 The 2024 ESC Guidelines (https://lnkd.in/eKvx7CFH) include a Class 1A recommendation for using IVUS or OCT imaging during PCI for anatomically complex lesions, such as left main stem, true bifurcations, and long lesions. These advanced imaging techniques, at the heart of what we do, are essential for providing unmatched precision in lesion assessment, vessel preparation, and treatment. Nipro's Makoto IVUS+NIRS (https://lnkd.in/dNSu--Dq) and Gentuity HF-OCT (https://lnkd.in/drJfhaAP) meet these guidelines' recommendations, ensuring we stay at the forefront of innovation. This new guidance represents a long awaited, big step forward for intravascular imaging, and we're proud to be part of innovation that contributes to better patient outcomes. #wearenipro #ESCGuidelines #intravascularimaging #innovation #patientoutcomes #IVUS #PCI #niprocardiovascular

Free “cheat sheet” page on IABP versus Impella. Comparisons between IABP and Impella are one of my top requested topics. Although, in my opinion, these are drastically different devices - I completely understand the need for clarity between the two. In the labs, there is a common debate between which to use. Once you start to understand the intricacies behind each device, you will begin to realize how different they actually are and which patients they’re most appropriate for. I hope this helps! #chatlab #iabp #impella #interventionalcardiology #medicaldevices #education

Medtronic Academy is your key to understanding how the Inceptiv™ SCS system with closed-loop technology is revolutionizing spinal cord stimulation (SCS) therapy. See risk info: https://bit.ly/3Ab1DG3 Access industry-leading webinars, courses, and resources that show the potential impact of the Inceptiv™ SCS system on your patients’ therapy and lives: • Automatic closed-loop technology • Full-body 1.5T and 3T MRI conditional access • Smallest and thinnest neurostimulator See more: https://bit.ly/3LW4aq6 #MDTPainInterventions #InceptivSCS #SCS #MedtronicAcademy #DestinationMedtronic Product usage represented may not be approved or cleared in all markets.